Overall, it is clear that APP perturbation, by increasing tumor immunogenicity and widening the range of tumor antigens presented could provide an excellent opportunity to stimulate the immune response and increase the efficacy of to ICI therapy. The gene discussed is APP; the disease is neoplasm.